Pharma Has More Data Than Ever, This Doesn’t Mean It Has Better Intelligence

How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

As leaders, we must evaluate solutions to fragmentation by asking the right questions.

As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.

Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.

Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.